RxDoctor Payments Data

Adam Pflugrath, MD

Retina Specialist · Greenville, SCNPI 1134515042

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,515 of the $13,084 with a category attached, or 65.1%. Genentech USA, Inc. accounts for 70.5% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $10,028, more than ten times the $975 reported in 2019.

$13,084in general payments, 2019–2025

Across 149 payments — averaging $87.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$9K
  • AbbVie$830
  • Alcon$826
  • Astellas Pharma US Inc$824
  • Novartis$265
  • Regeneron$179
  • plus $942 from 14 others

What the payments were for

  • Consulting fees$8,51565%
  • Travel & lodging$5004%
  • Food & beverage$4,06831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,084 in reported general payments places this provider in the 85th percentile of 20 retina specialist providers in South Carolina.

See all retina specialist providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,550,940
Medicare patients
1,034
Services billed
144,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium23$11,624
IlevroNepafenac22$9,627
Bromfenac Sodium33$5,568
Prednisolone Acetate53$2,495
Difluprednate22$2,091
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha144$1,416
Ketorolac Tromethamine25$478
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$450
MoxifloxacinMoxifloxacin Hcl29$411
Latanoprost20$208
Timolol Maleate22$157
Brimonidine Tartrate23$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$265$9,62722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 retina specialist providers in South Carolina.

Other retina specialist in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →